Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 5/20 | 0.68 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.68 |
| ▸ | TUBB | P07437 | 2/20 | 0.68 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.68 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.68 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.68 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.68 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.68 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.68 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.68 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.68 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.68 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.68 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.68 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.68 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.68 |
| ▸ | ABL1 | P00519 | 1/20 | 0.68 |
| ▸ | LYN | P07948 | 1/20 | 0.68 |
| ▸ | BCR | P11274 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL254273 | 0.90 | TUBB4A (0.72) | SRCTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL30727814 | 0.87 | TUBB4A (0.68) | SRCTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL155785 | 0.87 | TUBB4A (0.68) | SRCTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL12158775 | 0.82 | NPC1 (0.62) | SRCTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL10132862 | 0.82 | TUBB4A (0.73) | SRCTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL10085622 | 0.82 | SRC (0.59) | SRCTUBB4ATUBBTUBA3CTUBA1B | |
| Tirbanibulin SCHEMBL153779 | 0.81 | TUBB4A (1.00) | SRCTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL10132860 | 0.81 | TUBB4A (0.71) | SRCTUBB4ATUBBTUBA3CTUBA1B | |
| Tirbanibulin SCHEMBL29386081 | 0.81 | TUBB4A (1.00) | SRCTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL1395845 | 0.81 | LTA4H (0.61) | NPC1RAB9AGAASMN1; SMN2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11752156-B2 | Compositions and methods for treating hyperproliferative skin disorders | Athenex HK Innovative Limited (HK) | 2023-09-12 | — | — | US | disclosed |
| US-20210038608-A1 | Compositions and Methods for Treating Hyperproliferative Skin Disorders | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2021-02-11 | — | — | US | disclosed |
| US-7851470-B2 | Composition and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851470-B2 | Composition and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2010-12-14 | — | — | US | disclosed |
| WO-2008082637-A9 | COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS LLC (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20080221102-A1 | Composition and methods for modulating a kinase cascade | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2008-09-11 | — | — | US | disclosed |
| US-20080221102-A1 | Composition and methods for modulating a kinase cascade | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2008-09-11 | — | — | US | disclosed |
| WO-2008082637-A1 | COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS, LLC (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221102-A1 | Composition and methods for modulating a kinase cascade | MAP3K4, MAP3K6, MAP3K3 | SRC 82/4885TUBB4A 2746/4885TUBB 2407/4885 |
| US-11752156-B2 | Compositions and methods for treating hyperproliferative skin disorders | CCND1, PRKD1, CCND3 | SRC 13/4885TUBB4A 81/4885TUBB 64/4885 |
| US-20210038608-A1 | Compositions and Methods for Treating Hyperproliferative Skin Disorders | CCND1, PRKD1, CCND3 | SRC 13/4885TUBB4A 81/4885TUBB 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.